1. Home
  2. Research
  3. Centers & Labs
  4. RIKEN Center for Integrative Medical Sciences

RIKEN Center for Integrative Medical Sciences Laboratory for Human Disease Models

Team Director: Fumihiko Ishikawa (M.D., Ph.D)

Research Summary

Fumihiko  Ishikawa(M.D., Ph.D)

The biggest goal of The Ishikawa lab is to develop curative treatments for leukemia. The laboratory pioneered xenograft models for normal human hematopoiesis and patient-derived xenograft (PDX) model for hematologic malignancies using NOD/SCID/IL2rgKO (NSG) mice, in collaboration with Dr. Leonard Shultz at The Jackson Laboratory . Through multi-faceted approach to human leukemia integrating evaluation using PDX models, computational chemistry, structural biology and single cell genomics, Dr. Ishikawa and the team members endeavor to understand the biology of difficult-to-treat hematologic malignancies and find new therapeutic options that tailor to individual patients with highly heterogeneous pathophysiology.

Main Research Fields

  • Medicine, Dentistry & Pharmacy

Related Research Fields

  • Biological Sciences

Keywords

  • Hematopoietic stem cell
  • Leukemia stem cell
  • Humanized mouse
  • Human immunology

Selected Publications

  • 1. Ari Itoh-Nakadai*, Minggao Liang*, Michiho Shindo, Chen Bibi, Mariko Tomizawa-Murasawa, Saera Fujiki, Akiko Kaneko, Emi Kanamaru, Mari Hashimoto, Hiroshi Kajita, Yoshinari Ando, Miki Kojima, Jonathan Moody, Makoto Iwasaki, Shinsuke Takagi, Ryo Nakagawa, Saumya Agrawal, Hanae Amitani-Iijima, Kaori Sato, Yuriko Sorimachi, Nahoko Suzuki, Takehiro Fukami, Takehisa Matsumoto, Mikako Shirouzu, Yuho Najima, Keiyo Takubo, Chung Chau Hon, Naoyuki Uchida, Shuichi Taniguchi, Yukihide Momozawa, Piero Carninci, Leonard D. Shultz, Yoriko Saito, Michiel de Hoon, Jay W. Shin, Fumihiko Ishikawa (* equally contributed authors).:
    "CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting."
    Nature Communications, doi: 10.1038/s41467-025-67745-x
  • 2. Hashimoto M, Saito Y, Nakagawa R, Ogahara I, Takagi S, Takata S, Amitani H, Endo M, Yuki H, Jordan A. Ramilowski, Jessica Severin, Manabe R, Watanabe T, Ozaki K, Kaneko A, Kajita H, Fujiki S, Sato K, Honma T, Uchida N, Fukami T, Okazaki Y, Ohara O, Leonard D. Shultz, Yamada M, Taniguchi S, Paresh Vyas, Michiel de Hoon, Momozawa Y, Ishikawa F.:
    "Maximal Therapeutic Vulnerability Converges on XIAP and BCL2 in Aggressive Acute Myeloid Leukemia with Diverse Genetic Aberrations."
    Nature Cancer, 340-356, 2021
  • 3.Saito Y, Shultz LD, Ishikawa F.:
    "Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice"
    Trends Immunol. 2020 Aug;41(8):706-720. doi: 10.1016/j.it.2020.06.004
  • 4.Saito Y, Mochizuki Y, Ogahara I, Watanabe T, Hogdal L, Takagi S, Sato K, Kaneko A, Kajita H, Uchida N, Fukami T, Shultz LD, Taniguchi S, Ohara O, Letai AG, Ishikawa F.:
    "Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways"
    Science Translational Medicine eaao1214, 2017.
  • 5.Saito Y, Yuki H, Kuratani M, Hashizume Y, Takagi S, Honma T, Tanaka A, Shirouzu M, Mikuni J, Handa N, Ogahara I, Sone A, Najima Y, Tomabechi Y, Wakiyama M, Uchida N, Tomizawa-Murasawa M, Kaneko A, Tanaka S, Suzuki N, Kajita H, Aoki Y, Ohara O, Shultz LD, Fukami T, Goto T, Taniguchi S, Yokoyama S and Ishikawa F.:
    "A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivor"
    Sci Transl Med 5, 181ra52, 2013.
  • 6.Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa-Murasawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F.:
    "Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnull humanized mice."
    Proc Natl Acad of Sci U S A 107, 13022-7, 2010.
  • 7.Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, Taniguchi S, Shultz LD, Ishikawa F.:
    "Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML"
    Nat Biotechnol 28, 275-80, 2010.
  • 8.Saito Y, KitamuraH, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N, Suzuki N, Sone A, Najima Y, Ozawa H, Wake A, Taniguchi S, Shultz LD, Ohara O, Ishikawa F.:
    "Identification for therapeutic targets for quiescent chemotherapy-resistant human AML stem cells"
    Sci Transl Med 2, 17ra9, 2010.
  • 9.Ishikawa F, Yoshika S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD.:
    "Chemotherapy-resistant human AML stem cells home to and engraft within the bone marrow endosteal region"
    Nat Biotechnol 25, 1315-21, 2007.
  • 10.Shultz LD, Ishikawa F, Greiner DL.:
    "Humanized mice in translational biomedical research"
    Nat Rev Immunol 7, 118-30, 2007.

Recent Research Results

Related Links

Lab Members

Principal investigator

Fumihiko Ishikawa
Team Director

Core members

Yoriko Saito
Senior Research Scientist
Anne De Groot
Special Postdoctoral Researcher
Kaori Sato
Technical Staff I
Mariko Tomizawa-Murasawa
Technical Staff II
Hiroshi Kajita
Technical Staff II
Saera Fujiki
Technical Staff II
Akiko Kaneko
Technical Staff II
Nahoko Suzuki
Technical Staff II
Emi Kanamaru
Student Trainee
Michiho Shindo-Ebihara
Student Trainee

Contact Information

1-7-22 Suehiro-cho, Tsurumi-ku,
Yokohama City, Kanagawa,
230-0045, Japan
Tel: +81-(0)45-503-9448
Fax: +81-(0)45-503-7068
Email: fumihiko.ishikawa [at] riken.jp

Top